Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CADL Candel Therapeutics, Inc.

Pre-Mkt 04-13 08:40:31 EDT

4.83

+0.03

+0.63%

盘前4.82

-0.01-0.21%

08:14 EDT

High4.86	Low4.76	Vol590.86K
Open4.82	D1 Closing4.80	Amplitude2.08%
Mkt Cap353.77M	Tradable Cap219.66M	Total Shares73.24M
T/O2.84M	T/O Rate1.30%	Tradable Shares45.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CADL","market":"US","secType":"STK","nameCN":"Candel Therapeutics, Inc.","latestPrice":4.83,"timestamp":1775851200000,"preClose":4.8,"halted":0,"volume":590855,"hourTrading":{"tag":"盘前","latestPrice":4.82,"preClose":4.83,"latestTime":"08:14 EDT","volume":2092,"amount":10086.471308,"timestamp":1776082483561,"change":-0.01,"changeRate":-0.00207,"amplitude":0.013002},"delay":0,"changeRate":0.006250000000000052,"floatShares":45478500,"shares":73244500,"eps":-0.720977,"marketStatus":"Pre-Mkt","change":0.03,"latestTime":"04-13 08:40:31 EDT","open":4.82,"high":4.86,"low":4.76,"amount":2844292.659445,"amplitude":0.020833,"askPrice":5.09,"askSize":99,"bidPrice":4.39,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.720977,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1776087000000},"marketStatusCode":1,"adr":0,"listingDate":1627358400000,"exchange":"NASDAQ","adjPreClose":4.83,"preHourTrading":{"tag":"盘前","latestPrice":4.82,"preClose":4.83,"latestTime":"08:14 EDT","volume":2092,"amount":10086.471308,"timestamp":1776082483561,"change":-0.01,"changeRate":-0.00207,"amplitude":0.013002},"postHourTrading":{"tag":"盘后","latestPrice":4.84,"preClose":4.83,"latestTime":"19:53 EDT","volume":6519,"amount":31506.595,"timestamp":1775865222580,"change":0.01,"changeRate":0.00207,"amplitude":0.00207},"volumeRatio":0.5456187540011392,"impliedVol":2.4213,"impliedVolPercentile":0.8233},"requestUrl":"/m/hq/s/CADL/wiki","defaultTab":"wiki","newsList":[{"id":"2624682860","title":"Candel Therapeutics grants 70,000 inducement stock options to five new employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2624682860","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624682860?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:08","pubTimestamp":1775160535,"startTime":"0","endTime":"0","summary":"Candel Therapeutics compensation committee granted inducement stock options covering 70,000 common shares to five new employees on March 31, 2026.Options carry exercise price of $4.90 per share.Vesting schedule sets 25% on first anniversary of each employee start date.Remaining 75% vests in 36 equal monthly installments.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL9tyBT7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","SG9999014013.SGD","IE00BN0W2V16.EUR","SG9999014021.USD","BK4139","BK4585","IE00B64PRP62.GBP","SG9999014005.SGD","CADL","LU2210149790.SGD","LU2095319765.USD","LU0314104364.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","NDAQ","IE00BKPKM429.USD","IE00BN0W2W23.USD","BK4112","IE00BN0W2T93.GBP","BK4588","BK4539","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624468230","title":"Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624468230","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624468230?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:05","pubTimestamp":1775160300,"startTime":"0","endTime":"0","summary":"NEEDHAM, Mass., April  02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biolog","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/02/3267831/0/en/Candel-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623586841","title":"Insider Purchases Worth US$3.00m See Losses As Candel Therapeutics Market Value Drops To US$352m","url":"https://stock-news.laohu8.com/highlight/detail?id=2623586841","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623586841?lang=en_us&edition=fundamental","pubTime":"2026-03-31 18:50","pubTimestamp":1774954247,"startTime":"0","endTime":"0","summary":"The recent 10% drop in Candel Therapeutics, Inc.'s ( NASDAQ:CADL ) stock could come as a blow to insiders who purchased...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cadl/candel-therapeutics/news/insider-purchases-worth-us300m-see-losses-as-candel-therapeu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cadl/candel-therapeutics/news/insider-purchases-worth-us300m-see-losses-as-candel-therapeu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4539","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620257754","title":"Candel Therapeutics Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2620257754","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620257754?lang=en_us&edition=fundamental","pubTime":"2026-03-18 23:13","pubTimestamp":1773846780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CADL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2026 11:13 ET (15:13 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620906232","title":"Candel Therapeutics Inc : Citigroup Raises Target Price to $26 From $22","url":"https://stock-news.laohu8.com/highlight/detail?id=2620906232","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620906232?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:42","pubTimestamp":1773830550,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN4060OQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620238304","title":"U.S. RESEARCH ROUNDUP-Factset, Lensar, Starbucks","url":"https://stock-news.laohu8.com/highlight/detail?id=2620238304","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620238304?lang=en_us&edition=fundamental","pubTime":"2026-03-18 15:36","pubTimestamp":1773819417,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Factset, Lensar, StarbucksMarch 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Wednesday, including Fa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nL8N4060HY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COHX","FDS","BTGO","CCL","XYZG","BKKT","CTMX","CALM","DOW","GLXY","ETR","BTSG","COHR","CLYM","CE","EQIX","STZ","DC","GLXU","HQY","DUOL","IE00BMG7P926.USD","CRC","ARCT","BL","GEMI","CF","LU2360107671.USD","ANDG","GLGG","ANRO","GEMG","XYZY","CLH","AJG","DOCU","ALDX","ECL","ASO","EVMN","FICO","APD","GHM","CADL","DTE","XYZ","LU1923621640.USD","DLR","APGE","LU1992135472.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620476752","title":"CAN-2409’s Emerging Survival Benefit and Biomarker-Driven Immunotherapy Platform Support Buy Rating and $23 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2620476752","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620476752?lang=en_us&edition=fundamental","pubTime":"2026-03-17 23:25","pubTimestamp":1773761115,"startTime":"0","endTime":"0","summary":"Andres Y. Maldonado, an analyst from H.C. Wainwright, reiterated the Buy rating on Candel Therapeutics. The associated price target remains the sam...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/can-2409s-emerging-survival-benefit-and-biomarker-driven-immunotherapy-platform-support-buy-rating-and-23-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/can-2409s-emerging-survival-benefit-and-biomarker-driven-immunotherapy-platform-support-buy-rating-and-23-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CADL","BK4595","BK4139","BK4600","BK4539","BK4170","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620242084","title":"Candel Therapeutics publishes corporate presentation on its viral immunotherapy cancer pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2620242084","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620242084?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:26","pubTimestamp":1773750369,"startTime":"0","endTime":"0","summary":"Candel outlined its lead program, aglatimagene besadenovec , describing it as an off-the-shelf therapy intended to generate an individualized immune response across solid tumors. The company said a randomized phase 3 trial in localized intermediate- to high-risk prostate cancer  met its primary endpoint of disease-free survival. Candel also cited phase 2a overall survival data for aglatimagene in borderline resectable pancreatic cancer and in therapy-resistant non-small cell lung cancer. It reported cash and cash equivalents of USD 119.7 million as of December 31, 2025 and said it entered into a term loan facility with Trinity Capital of up to USD 130 million. Candel also highlighted linoserpaturev , an oncolytic HSV-1 program for recurrent high-grade glioma, and noted Fast Track and Orphan Drug designations for that candidate.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely infor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL3TXQBm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRIN","BK4139","CADL","BK4135","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620424693","title":"BRIEF-Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec","url":"https://stock-news.laohu8.com/highlight/detail?id=2620424693","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620424693?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:14","pubTimestamp":1773749697,"startTime":"0","endTime":"0","summary":"BRIEF-Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene BesadenovecMarch 17 (Reuters) - Candel Therapeutics Inc CADL.O:CANDEL THERAPEUTICS INC: EXTENDED SURVIVAL TAIL OB","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nFWN40509G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CADL","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620424548","title":"Candel Therapeutics Inc: Phase 3 Pivotal Study Planned for Initiation in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620424548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620424548?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:12","pubTimestamp":1773749547,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nFWN40509G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","CADL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620424543","title":"Candel Therapeutics Inc: Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec","url":"https://stock-news.laohu8.com/highlight/detail?id=2620424543","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620424543?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:12","pubTimestamp":1773749547,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nFWN40509G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","CADL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620248114","title":"Candel Therapeutics reports 25.4-month median overall survival and 50% 24-month survival in CAN-2409 phase 2a NSCLC trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2620248114","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620248114?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:06","pubTimestamp":1773749177,"startTime":"0","endTime":"0","summary":"Candel reported an additional 12 months of follow-up from an ongoing phase 2a trial evaluating aglatimagene besadenovec  plus valacyclovir with continued immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients with inadequate response to prior immune checkpoint inhibitors. In the per-protocol population , 50% of patients were alive at 24 months and median overall survival was 25.4 months. In cohort 2  with progressive disease at baseline despite prior immune checkpoint inhibitor therapy, median overall survival was 21.5 months. Among patients surviving beyond 24 months with PD-L1 status available , 85% had baseline PD-L1 tumor proportion scores below 50%. The company said it plans to initiate a phase 3 trial in the second quarter of 2026 in patients with non-squamous histology.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDLbkPfM9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","BK4539","IE00B3QW5Z07.USD","BK4112","LU2210150020.SGD","CADL","IE00BN0W2V16.EUR","SG9999014013.SGD","SG9999014005.SGD","LU2210149790.SGD","BK4139","IE00BN0W2T93.GBP","LU0314104364.USD","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014039.USD","NDAQ","BK4588","BK4585","IE00BN0W2W23.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619112601","title":"Candel Therapeutics Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2619112601","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619112601?lang=en_us&edition=fundamental","pubTime":"2026-03-14 02:20","pubTimestamp":1773426000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CADL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 13, 2026 14:20 ET (18:20 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619761163","title":"Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2619761163","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619761163?lang=en_us&edition=fundamental","pubTime":"2026-03-13 14:01","pubTimestamp":1773381678,"startTime":"0","endTime":"0","summary":"Candel Therapeutics, Inc. (CADL) has disclosed a new risk, in the Debt & Financing category. The analyst notes that covenants in the RTW Purchase A...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/restrictive-rtw-purchase-agreement-covenants-threaten-candel-therapeutics-financial-flexibility-and-increase-default-risk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/restrictive-rtw-purchase-agreement-covenants-threaten-candel-therapeutics-financial-flexibility-and-increase-default-risk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CADL","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618134960","title":"Candel Therapeutics Q4 EPS $(0.54) Misses $(0.24) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2618134960","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618134960?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:25","pubTimestamp":1773318310,"startTime":"0","endTime":"0","summary":"Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.24) by 120.41 percent. This is a 35 percent decrease over losses of $(0.40) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51209765/candel-therapeutics-q4-eps-0-54-misses-0-24-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618113453","title":"Candel Therapeutics Q4 operating loss misses analyst expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2618113453","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618113453?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:17","pubTimestamp":1773317837,"startTime":"0","endTime":"0","summary":"Candel Therapeutics Q4 operating loss misses analyst expectationsOverviewUS cancer immunotherapy developer's Q4 operating loss missed analyst expectationsQ4 net loss widened to $29.5 mln from $14.1 ml","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nL1N4000LK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CADL","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618134589","title":"BRIEF-Candel Therapeutics Q4 Net Income USD -29.496 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618134589","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618134589?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:05","pubTimestamp":1773317145,"startTime":"0","endTime":"0","summary":"BRIEF-Candel Therapeutics Q4 Net Income USD -29.496 Million\n\n\nMar 12 (Reuters) - Candel Therapeutics Q4 operating expenses USD 15.752 million.\n\nQ4 income from operations USD -15.752 million vs. IBES estimate USD -13.9 million\nQ4 basic EPS USD -0.54","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nPLXC67129:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CADL","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618613179","title":"Candel Therapeutics Q4 Income From Operations USD -15.752 Million VS. Ibes Estimate USD -13.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618613179","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618613179?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:05","pubTimestamp":1773317101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nPLXC67129:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CADL","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618013179","title":"Candel Therapeutics Q4 Basic EPS USD -0.54","url":"https://stock-news.laohu8.com/highlight/detail?id=2618013179","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618013179?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:05","pubTimestamp":1773317101,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nPLXC67129:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CADL","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618131098","title":"Press Release: Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2618131098","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618131098?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:05","pubTimestamp":1773317100,"startTime":"0","endTime":"0","summary":"-- Company plans to initiate a pivotal phase 3 clinical trial of. despite immune checkpoint inhibitor  treatment, in Q2 2026. -- Company plans to submit a Biologics License Application  for. aglatimagene in localized, intermediate-to high-risk prostate cancer in. -- Company announced investigational new drug  clearance for. support enabling work for a potential future randomized controlled phase. -- Entered into a $130 million term loan facility with Trinity Capital Inc. with $50 million drawn down at closing, and access of. -- Cash and cash equivalents of $119.7 million, as of December 31, 2025,together with $93.5 million in net proceeds from the February 2026. follow-on equity offering, strengthens the Company's financial position. and is sufficient to fund the current operating plan into Q1 2028, which. includes activities to support the potential commercial launch of. NEEDHAM, Mass., March 12, 2026  -- Candel Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0149725797.USD","LU0267386448.USD","IE00B1BXHZ80.USD","BK4588","BK4585","LABU","LU2746668974.SGD","LU2237443549.SGD","LU2237443895.HKD","CMC","LU2237443465.HKD","LU2237443382.USD","LU0882574139.USD","LU0170899867.USD","BK4539","IE00BFXG1179.USD","LU1363072403.SGD","IE00BKVL7J92.USD","LU2746668461.USD","BK4006","CADL","IE00BHPRN162.USD","LU2237443622.USD","IND","LU0971096721.USD","LU2237443978.SGD","BK4139","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.candeltx.com","stockEarnings":[{"period":"1week","weight":-0.034},{"period":"1month","weight":-0.0529},{"period":"3month","weight":-0.1541},{"period":"6month","weight":-0.2197},{"period":"1year","weight":0.0126},{"period":"ytd","weight":-0.1451}],"compareEarnings":[{"period":"1week","weight":0.036},{"period":"1month","weight":0.0046},{"period":"3month","weight":-0.021},{"period":"6month","weight":0.0405},{"period":"1year","weight":0.2952},{"period":"ytd","weight":-0.0036}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.056687},{"month":2,"riseRate":0.4,"avgChangeRate":0.052018},{"month":3,"riseRate":0.2,"avgChangeRate":-0.120448},{"month":4,"riseRate":0.2,"avgChangeRate":0.595132},{"month":5,"riseRate":1,"avgChangeRate":0.149002},{"month":6,"riseRate":0,"avgChangeRate":-0.170269},{"month":7,"riseRate":0.25,"avgChangeRate":0.011025},{"month":8,"riseRate":0.8,"avgChangeRate":0.068985},{"month":9,"riseRate":0.4,"avgChangeRate":-0.01705},{"month":10,"riseRate":0.4,"avgChangeRate":-0.110246},{"month":11,"riseRate":0,"avgChangeRate":-0.079739},{"month":12,"riseRate":0.8,"avgChangeRate":0.288433}],"exchange":"NASDAQ","name":"Candel Therapeutics, Inc.","nameEN":"Candel Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Candel Therapeutics, Inc.(CADL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Candel Therapeutics, Inc.,CADL,Candel Therapeutics, Inc.股票,Candel Therapeutics, Inc.股票老虎,Candel Therapeutics, Inc.股票老虎国际,Candel Therapeutics, Inc.行情,Candel Therapeutics, Inc.股票行情,Candel Therapeutics, Inc.股价,Candel Therapeutics, Inc.股市,Candel Therapeutics, Inc.股票价格,Candel Therapeutics, Inc.股票交易,Candel Therapeutics, Inc.股票购买,Candel Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Candel Therapeutics, Inc.(CADL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}